Nintedanib Ratiopharm (Nintedanib)

Nintedanib inhibits several receptor tyrosine kinases—VEGFR, FGFR and PDGFR. Blocking these signals reduces fibroblast activity, limits abnormal tissue remodeling, and suppresses angiogenesis, which together contribute to its antifibrotic and anti‑angiogenic effects.

The dose of Nintedanib Ratiopharm is determined by the prescribing clinician based on the specific indication, patient characteristics and tolerability. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for each individual.

Nintedanib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is contraindicated during pregnancy, and breastfeeding is not recommended because the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both slow disease progression, Nintedanib targets a broader range of tyrosine kinases, offering additional anti‑angiogenic activity, whereas pirfenidone works mainly through anti‑inflammatory and antioxidant pathways. Choice depends on patient tolerance, comorbidities and physician judgment.

Nintedanib Ratiopharm capsules should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct heat, and store out of reach of children.

The medication is taken orally as a capsule, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary considerations.

Clinicians and patients should be alert for signs of hepatic failure (elevated liver enzymes, jaundice), arterial thromboembolic events (chest pain, sudden weakness, stroke symptoms) and severe bleeding (unexplained bruising, blood in stool or urine). Prompt medical evaluation is essential if any of these occur.

Nintedanib is contraindicated in pregnant women, patients with severe hepatic impairment, active uncontrolled bleeding, or a recent history of arterial thromboembolic events. Caution is also advised for individuals with significant cardiovascular disease, uncontrolled hypertension, or those taking strong CYP3A4 inducers or inhibitors without appropriate monitoring.